Eli Lilly & Co. said Friday its blockbuster antidepressant Cymbalta will have an additional six months of U.S. market exclusivitythrough December 2013because the company studied the drug's effects on children. Lilly said, however, that it won't seek regulatory approval to market Cymbalta for...
FULL ARTICLE AT Asian Wall Street Journal